4.4 Article

Short Chain Fatty Acids, pancreatic dysfunction and type 2 diabetes

Journal

PANCREATOLOGY
Volume 19, Issue 2, Pages 280-284

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.pan.2019.01.021

Keywords

Pancreatic dysfunction; Short chain fatty acids; GLP1; Insulin; Glucagon; Hyperglycemia; T2D

Funding

  1. University Grant Commission (UGC), Government of India [372817]
  2. Nirma Education and Research Foundation (NERF), Ahmedabad

Ask authors/readers for more resources

The microbiota living in gut influence the immune response, metabolism, mood and behavior. The diet plays a pivotal role in maintaining healthy gut microbiota composition and its fermentation leads to production of Short Chain Fatty Acids (SCFAs) mainly acetate, propionate and butyrate. During pancreatic dysfunction, insulin mediated suppression of glucagon is impaired leading to uncontrolled glucose production by liver and state of hyperglycemia. Insulin and glucagon balance is as important as insulin sensitivity which is reduced during Type 2 Diabetes (T2D). Glucagon like peptide-1 (GLP1) produced by Intestinal epithelial cells regulates insulin and glucagon secretion directly via GLP1 receptor on pancreatic cells or via nervous system. But half-life period of GLP1 is very short i.e. about 2 min, after which it is cleaved and inactivated. SCFAs are well documented to induce GLP1 but its direct effect on pancreatic dysfunction has not been reported. This review opens a new avenue to study the role of SCFAs as treatment to pancreatic dysfunction and T2D. (C) 2019 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available